⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337322 | 1.00 | — | — | |
| SCHEMBL272583 | 0.75 | — | — | |
| Alanine SCHEMBL20582916 | 0.74 | — | — | |
| Alanine SCHEMBL27461491 | 0.74 | — | — | |
| Alanine SCHEMBL11180815 | 0.74 | — | — | |
| Alanine SCHEMBL254290 | 0.72 | SLC7A5 (0.59) | — | |
| Alanine SCHEMBL452350 | 0.72 | SLC7A5 (0.59) | — | |
| Alanine SCHEMBL14764702 | 0.72 | SLC7A5 (0.59) | — | |
| D-Alanine SCHEMBL614024 | 0.72 | SLC7A5 (0.59) | — | |
| SCHEMBL12134091 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220214354-A1 | MEANS AND METHODS FOR SINGLE MOLECULE PEPTIDE SEQUENCING | VIB VZW (BE) | 2022-07-07 | — | — | US | disclosed |
| EP-3948297-A1 | MEANS AND METHODS FOR SINGLE MOLECULE PEPTIDE SEQUENCING | VIB VZW (BE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201350-A1 | MEANS AND METHODS FOR SINGLE MOLECULE PEPTIDE SEQUENCING | VIB VZW (BE) | 2020-10-08 | — | — | WO | disclosed |
| EP-1906971-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-4760180-A | N-terminally substituted dipeptide amides | G. D. SEARLE & CO. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0213481-A2 | N-terminally substituted dipeptide amides No. 2 | G.D. Searle & Co. (US) | 1987-03-11 | — | — | EP | disclosed |